Literature DB >> 20638642

Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses.

Frank Kirchhoff1.   

Abstract

Retroviruses have evolved effective strategies to evade the host immune response, such as high variability and latent infection. In addition, primate lentiviruses, such as HIV-1, have acquired several "accessory" genes that antagonize antiviral host restriction factors and facilitate viral immune evasion, thereby allowing continuous and efficient viral replication despite apparently strong innate and acquired immune responses. Here, I summarize some of our current knowledge on the acquisition and function of the viral vif, vpr, vpu, and nef genes, with a particular focus on the evolution and specific properties of pandemic HIV-1 strains that may contribute to their efficient spread and high virulence. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638642     DOI: 10.1016/j.chom.2010.06.004

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  168 in total

1.  HIV-1 Vpu disarms natural killer cells.

Authors:  Jonathan Richard; Éric A Cohen
Journal:  Cell Host Microbe       Date:  2010-11-18       Impact factor: 21.023

2.  Vpu-deficient HIV strains stimulate innate immune signaling responses in target cells.

Authors:  Brian P Doehle; Kristina Chang; Lamar Fleming; John McNevin; Florian Hladik; M Juliana McElrath; Michael Gale
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

3.  The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx.

Authors:  Efrem S Lim; Oliver I Fregoso; Connor O McCoy; Frederick A Matsen; Harmit S Malik; Michael Emerman
Journal:  Cell Host Microbe       Date:  2012-01-26       Impact factor: 21.023

4.  Vpu mediates depletion of interferon regulatory factor 3 during HIV infection by a lysosome-dependent mechanism.

Authors:  Brian P Doehle; Kristina Chang; Arjun Rustagi; John McNevin; M Juliana McElrath; Michael Gale
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

5.  Experimental Adaptive Evolution of Simian Immunodeficiency Virus SIVcpz to Pandemic Human Immunodeficiency Virus Type 1 by Using a Humanized Mouse Model.

Authors:  Kei Sato; Naoko Misawa; Junko S Takeuchi; Tomoko Kobayashi; Taisuke Izumi; Hirofumi Aso; Shumpei Nagaoka; Keisuke Yamamoto; Izumi Kimura; Yoriyuki Konno; Yusuke Nakano; Yoshio Koyanagi
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

Review 6.  Innate antiviral immune signaling, viral evasion and modulation by HIV-1.

Authors:  Arjun Rustagi; Michael Gale
Journal:  J Mol Biol       Date:  2013-12-08       Impact factor: 5.469

7.  The DDB1-DCAF1-Vpr-UNG2 crystal structure reveals how HIV-1 Vpr steers human UNG2 toward destruction.

Authors:  Ying Wu; Xiaohong Zhou; Christopher O Barnes; Maria DeLucia; Aina E Cohen; Angela M Gronenborn; Jinwoo Ahn; Guillermo Calero
Journal:  Nat Struct Mol Biol       Date:  2016-08-29       Impact factor: 15.369

8.  An intronic G run within HIV-1 intron 2 is critical for splicing regulation of vif mRNA.

Authors:  Marek Widera; Steffen Erkelenz; Frank Hillebrand; Aikaterini Krikoni; Darius Widera; Wolfgang Kaisers; René Deenen; Michael Gombert; Rafael Dellen; Tanya Pfeiffer; Barbara Kaltschmidt; Carsten Münk; Valerie Bosch; Karl Köhrer; Heiner Schaal
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

9.  Modulation of HIV pathogenesis and T-cell signaling by HIV-1 Nef.

Authors:  Shailendra K Saxena; Gaurav Shrivastava; Sneham Tiwari; Ml Arvinda Swamy; Madhavan Pn Nair
Journal:  Future Virol       Date:  2012-06-01       Impact factor: 1.831

10.  Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice.

Authors:  Eun Mi Hur; Sonal N Patel; Saki Shimizu; Dinesh S Rao; Priyanthi N P Gnanapragasam; Dong Sung An; Lili Yang; David Baltimore
Journal:  Blood       Date:  2012-10-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.